SCHEMBL10102670

SCHEMBL10102670

CCc1ccc2nc(-c3ccccc3)c(CCCO)cc2c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 2/20 0.47
PDE3B Q13370 2/20 0.41
PDE3A Q14432 2/20 0.41
P2RY12 Q9H244 2/20 0.41
PDE10A Q9Y233 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
ATM Q13315 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TLR8 Q9NR97 3/20 0.38
MAPT P10636 1/20 0.38
GRM1 Q13255 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2A6 P11509 1/20 0.37
PTGFR P43088 1/20 0.37
DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3387112 0.92 PSMB5 (0.46) PSMB5PDE10AKMT2AMEN1ALDH1A1
SCHEMBL10102668 0.86 PSMB5 (0.44) PSMB5PDE10ATLR8MAPT
SCHEMBL10102667 0.85 PSMB5 (0.43) PSMB5PDE10AKMT2AMEN1ALDH1A1
SCHEMBL10102628 0.82 DHODH (0.46) PSMB5PDE10AKMT2AALDH1A1HPGD
SCHEMBL13005210 0.81 AKT1 (0.39) PSMB5PDE10AKMT2AALDH1A1HPGD
SCHEMBL10102635 0.81 PSMB5 (0.39) PSMB5PDE10AKMT2AALDH1A1HPGD
SCHEMBL10102630 0.79 KMT2A (0.38) PSMB5PDE10AKMT2AMEN1ALDH1A1
SCHEMBL3383001 0.79 DHODH (0.45) KMT2AATMKDM4EDHODH
SCHEMBL10102632 0.78 DHFR (0.41) PDE3BPDE3AP2RY12PDE10AKMT2A
SCHEMBL10107721 0.78 PSMB5 (0.39) PSMB5PDE10AKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B PSMB5 228/4885PDE3B 3952/4885PDE3A 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.